The ONCOMINE analysis indicated significant upregulation of MSI2 in lung cancer compared to adjacent normal tissues, as well as in breast cancer, colon cancer, gastric cancer, and leukemia (Figure 1A). This evidence concerns the gene MSI2 and breast carcinoma.